{"id":"W2766948867","doi":"10.1182/blood-2017-06-791228","title":"Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Ixazomib; Multiple myeloma; Progression-free survival; Refractory (planetary science); Medicine; Lenalidomide; Oncology; Internal medicine; Pomalidomide; Overall survival; Carfilzomib; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002748485,0.0002122878,0.000389243,0.0001087005,0.00008881239,0.0002411739,0.00009390641,0.00015092,0.002064403],"category_scores_gemma":[0.000362151,0.00008670478,0.00024109,0.0001637237,0.0001089991,0.0001176635,0.0001120307,0.0004739424,0.0002406647],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003618156,"about_ca_system_score_gemma":0.0002373445,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009367183,"about_ca_topic_score_gemma":0.004192219,"domain_scores_codex":[0.9999286,0.00002872788,0.000003888348,0.00001070318,0.00001201753,0.00001599405],"domain_scores_gemma":[0.9998848,0.00002577219,0.00003913208,0.000005056343,0.000005081044,0.00004015049],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4091928,0.002288654,0.04888666,0.002052727,0.002857753,0.0005573322,0.0001640242,0.002616476,0.04780909,0.0005376752,0.01822067,0.4648161],"study_design_scores_gemma":[0.1487493,0.09318701,0.6960339,0.00058862,0.004133883,0.002484493,0.0001950268,0.007034752,0.01178563,0.001207032,0.03452534,0.00007509501],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9685612,0.02544468,0.0002154565,0.001062108,0.0001885647,0.00006764754,0.0005771547,0.000108073,0.003775178],"genre_scores_gemma":[0.9944377,0.003580236,0.0001700123,0.0001998489,0.00008318121,0.00001587682,0.0003930577,0.000003877033,0.001116144],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002064403,"threshold_uncertainty_score":0.006906152,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01918654123332542,"score_gpt":0.2931582333603844,"score_spread":0.273971692127059,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}